Firefly Neuroscience, Inc. AIFF
2.01
0.82
68.91%
as of 25 Sep
- Market cap
- $18.7M
- P/E
- 0.0×
Follow AIFF
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
13.84 | 22.33 | 9.59 | 50.17 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(14.23) | (18.16) | (6.07) | (26.40) | |
P/B ratio |
1.70 | 4.19 | 1.43 | 4.07 | |
Price to Tangible BV |
2.86 | 14.47 | 6.84 | 10.96 | |
EV/Sales |
8.95 | 20.63 | 7.56 | 45.20 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.30) | (4.28) | (1.05) | (4.65) | |
EV/FCF |
(2.20) | (4.11) | (1.02) | (4.46) | |
Quick Ratio |
4.49 | 1.35 | 1.04 | 1.66 | |
Current Ratio |
4.87 | 1.82 | 1.43 | 2.00 | |
Net Debt/EBITDA |
4.79 | 1.59 | 1.17 | 1.77 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.11 | 0.14 | 0.15 | 0.09 | |
Operating CF/Net income |
0.88 | 0.93 | 0.66 | 0.56 | |
Capex/Depreciation |
(0.89) | (1.29) | (0.15) | (0.41) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
102.14% | 87.42% | 110.68% | 97.42% | |
Selling, General and Administrative Expense of Revenue |
331.13% | 372.58% | 516.50% | 585.57% | |
Intangible Assets out of Total Assets |
0.36 | 0.55 | 0.58 | 0.49 | |
Share Based Compensation of Revenue |
69.26% | 119.59% | 136.41% | 27.58% | |
Graham Net Nets |
0.33 | 0.06 | 0.11 | 0.07 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(48.76%) | (28.90%) | (204.55%) | (71.82%) | |
Free Cash Flow Yield |
(29.46%) | (22.46%) | (77.24%) | (20.18%) | |
Revenue per Share |
0.03 | 0.03 | 0.03 | 0.03 | |
Operating CF per Share |
(0.08) | (0.12) | (0.15) | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.09) | (0.12) | (0.15) | (0.12) | |
Cash per Share |
0.45 | 0.19 | 0.22 | 0.32 | |
Shareholders Equity per Share |
0.71 | 0.52 | 0.61 | 0.72 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.71 | 0.52 | 0.61 | 0.72 | |
Free Cash Flow |
(1.79) | (2.01) | (1.83) | (1.57) | |
Working Capital |
8.13 | 2.01 | 1.21 | 2.71 | |
Capital Expenditures |
(0.04) | (0.06) | (0.02) | (0.09) | |
Net Current Asset Value |
8.12 | 1.99 | 1.19 | 2.68 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.08 | 0.12 | 0.06 | 0.22 | |
Net Profit Margin |
(385.99%) | (431.75%) | (659.95%) | (680.15%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.14 | 0.16 | 0.14 | 0.49 | |
Average Payables |
1.19 | 1.47 | 1.58 | 1.36 | |
Average Inventory |
0.09 | — | — | — | |
Average Assets |
15.85 | 11.64 | 7.54 | 8.86 | |
Average Common Equity |
13.38 | 6.81 | 3.63 | 6.22 |
Columns are period end dates